

## Positive Quality Intervention: Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

**Description:** This PQI will discuss the rationale for the clinical use of the oral DNMT/CDA inhibitor decitabine/cedazuridine (DEC-C) for the management of intermediate-1, intermediate-2, and high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

**Background:** DEC-C is a fixed-dose combination of the hypomethylating agent decitabine and the cytidine deaminase inhibitor cedazuridine, which prevents degradation of decitabine in the gastrointestinal tract and liver, thus allowing for its oral dosing and absorption.<sup>1</sup> It is indicated for the treatment of adult patients with MDS, including previously treated and untreated, de novo and secondary MDS with the following French American-British subtype (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and CMML) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

It has long been noted that the development of an oral DNMT inhibitor would alleviate much of the burden associated with the treatment of MDS/CMML for those patients on IV DNMT inhibitors. Specifically, an oral option would decrease clinic visits, reduce travel time associated with treatment, reduce the need for IV access and the associated infection risks, and decrease exposure to health facilities. Published data of the phase 1/2 trials as well as preliminary data of the phase 3 trial demonstrate the safety and efficacy of DEC-C.<sup>2-4</sup> The phase 3 ASCERTAIN trial compared IV decitabine to PO decitabine/cedazuridine, and enrolled 138 MDS intermediate, MDS high risk, and CMML patients. They were randomized 1:1 to one of two treatment arms - Sequence A (DEC-C 35 mg/100 mg daily x 5 days) in Cycle 1 followed by IV decitabine (20 mg/m<sup>2</sup> daily x 5 days) in Cycle 2, or Sequence B (IV decitabine 20 mg/m<sup>2</sup> daily x 5 days) in Cycle 1, followed by DEC-C (35 mg/100 mg daily x 5 days) in Cycle 2. All patients then received DEC-C on cycles 3 and onward. The study was conducted to demonstrate exposure bioequivalence between DEC-C and IV-DEC, comparing relevant pharmacokinetic (PK) and pharmacodynamic (PD) parameters, specifically the primary endpoint AUC equivalence over 5 days of dosing, and DNA methylation using the *LINE-1* assay, respectively. The 5-day oral:IV AUC ratio was 99%, demonstrating equivalent systemic exposure between the two formulations. The *LINE-1* assay demonstrated a difference of < 1% between the two formulations, which also confirmed the PK findings. The overall response rate from treatment was 65% (complete response + partial response + marrow CR + hematologic improvement), which is in line with what is seen with conventionally dosed IV decitabine. Transfusion independence was noted in 50% of patients in the phase 2 trial and 32.7% of patients in the phase 3 trial. There were no significant differences noted between the side effect profiles of the IV and PO formulations. Studies have indicated that a high proportion of patients discontinue HMA therapy before receiving the recommended course of  $\geq 4-6$  cycles and that patients that do not receive at least 4 cycles of have worse outcomes.<sup>5-8</sup> Therefore the proper management of these patients is of the utmost importance for outcomes.

### PQI Process:<sup>1</sup>

- Utilize the reporting tools available in the EMR to identify patients who are receiving IV decitabine for MDS or CMML and discuss the option of converting to oral DEC-C with their physician
- **Do NOT substitute DEC-C for an intravenous decitabine product within a cycle**
- Educate providers on the availability of decitabine to administer to patients as an alternative to traveling to the clinic for 5 consecutive days for IV infusion

**IMPORTANT NOTICE:** NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual's sole responsibility to seek guidance from a qualified healthcare professional. *Updated 11.14.23*

- Recommended dosage is 1 tablet (35 mg decitabine and 100 mg cedazuridine) PO once daily on Days 1 through 5 of each 28-day cycle (minimum 4 cycles) until disease progression/unacceptable toxicity
  - A complete or partial response may take longer than 4 cycles
- Obtain complete blood cell count and a comprehensive metabolic panel prior to initiating therapy and before each cycle
  - Delay the next cycle if absolute neutrophil count (ANC)  $\leq 1,000/\mu\text{L}$  and platelets  $\leq 50,000/\mu\text{L}$  in the absence of active disease
  - If hematologic recovery occurs (ANC  $\geq 1,000/\mu\text{L}$  and platelets  $\geq 50,000/\mu\text{L}$ ) within 2 weeks of achieving remission, continue at the same dose
  - If hematologic recovery does not occur within 2 weeks of achieving remission:
    - Delay up to 2 additional weeks AND resume at a reduced dose by administering on days 1 through 4; consider further dose reductions if myelosuppression persists
    - Maintain or increase dose in subsequent cycles as clinically indicated
    - Recommended dose reductions for myelosuppression
      - First dose reduction: 1 tablet PO once daily on days 1 through 4
      - Second dose reduction: 1 tablet PO once daily on days 1 through 3
      - Third dose reduction: 1 tablet PO once daily on days 1, 3 and 5
  - If serum bilirubin or AST/ALT  $\geq 2x$  ULN: Delay next cycle and resume at same or reduced dose

### Patient-Centered Activities:

- Provide an [Oral Chemotherapy Education Sheet](#)
- Educate patient on schedule of administration: 5 consecutive days every 4 weeks (eg., Monday-Friday)
- Educate patient to not consume food 1 hour before and 2 hours after each dose
- Discuss with patient the risks of infection associated with bone marrow suppression and how to mitigate
- Educate the patient on when to contact the care team:
  - Fever of 100.4 degrees Fahrenheit (38 degrees Celsius)
  - Nausea/vomiting: educate on alternating different antinausea medication
  - Unusual bleeding: bloody urine, black/tarry stools
  - Painful mouth sores
- Discuss the management (using dietary/lifestyle/pharmacologic strategies) of constipation and diarrhea
- Monitor lab values before each cycle, focusing on neutropenia and thrombocytopenia
- Educate to avoid taking over-the-counter medications that can increase bleeding risk (eg., aspirin, NSAIDs)
- Patient Assistance: [NCODA Financial Assistance Tool](#)

### References:

1. [Inqovi® \(decitabine and cedazuridine\) \[prescribing information\]. Princeton, NJ: Taiho Oncology.](#)
2. Savona, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. *Lancet Haematol* 2019; 6: e194-203
3. Garcia-Manero, et al. Oral Cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML. *Blood* April 2013. Epub ahead of print.
4. Garcia-Manero, et al. Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross-Over Phase 3 Study (ASCERTAIN) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. 61st ASH Annual Meeting, Orlando, FL. 2019. Abstract #846.
5. Demakos, Erin P., et al. "Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents." *Blood*, vol. 124, no. 21, 6 Dec. 2014, pp. 1287–1287, <https://doi.org/10.1182/blood.v124.21.1287.1287>.
6. Mukherjee, Sudipto, et al. "Treatment Patterns among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies." *Blood*, vol. 124, no. 21, 6 Dec. 2014, pp. 2598–2598, <https://doi.org/10.1182/blood.v124.21.2598.2598>.
7. Cheng, Wendy Y., et al. "Persistence to Hypomethylating Agents and Clinical and Economic Outcomes among Patients with Myelodysplastic Syndromes." *Hematology*, vol. 26, no. 1, 1 Jan. 2021, pp. 261–270, <https://doi.org/10.1080/16078454.2021.1889161>.
8. Zeidan, Amer M., et al. "Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients with Higher-Risk Myelodysplastic Syndromes." *Clinical Lymphoma Myeloma and Leukemia*, vol. 22, no. 9, Sept. 2022, pp. 670–679, <https://doi.org/10.1016/j.clml.2022.04.016>.